Carrier-antibody compositions and methods of making and using the same
AssigneeMayo Foundation for Medical Education and Research
InventorsSvetomir N. Markovic, Wendy K. Nevala
Life of this patent
Estimating the term…
Abstract
Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.
Claims11
A lyophilized composition comprising nanoparticle complexes having an outer surface, wherein each of the nanoparticle complexes comprises:
- albumin;
- between about 100 to about 1000 bevacizumab antibodies, each having a hydrophobic Fc portion and a VEGF-binding portion, wherein the VEGF-binding portion is arranged on the outer surface of the complex;
- and
- paclitaxel;
- said nanoparticle complexes being lyophilized, and wherein upon reconstitution with an aqueous solution the VEGF-binding portions of said antibodies remain arranged on the outer surface of the complexes and remain capable of binding to VEGF in vivo and the Fc portions are associated with said albumin;
- and further wherein said complexes have an average size of from about 130 nm to about 800 nm.
A lyophilized composition comprising nanoparticle complexes having an outer surface, wherein each of the nanoparticle complexes comprises:
- albumin;
- between about 100 to about 1000 bevacizumab antibodies, each having a hydrophobic Fc portion and a VEGF-binding portion, wherein the VEGF-binding portion is arranged on the outer surface of the complex;
- and
- paclitaxel;
- said nanoparticle complexes being lyophilized, and wherein upon reconstitution with an aqueous solution the VEGF-binding portions of said antibodies remain arranged on the outer surface of the complexes and remain capable of binding to VEGF in vivo and the Fc portions are associated with said albumin;
- and further wherein said complexes have an average size of from about 130 nm to about 800 nm;
- wherein the lyophilized composition does not contain a bulking agent.
Dependencies are inferred from the claim text.